2. Champion-Af Trial: A Prospective Multicenter Randomized Trial To Evaluate The Safety And Efficacy Of The Watchman Flx Laac Device Vs. Direct Acting Oral Anticoagulants For First-Line Therapy In The Prevention Of Stroke In Patients With Nonvalvular Afib

    Submitted by centretek on Sat, 10/15/2022 - 10:30

  4. Chronic Venous Thrombosis: Relief with Adjunctive Catheter-directed Therapy (C-TRACT)

    Submitted by centretek on Sat, 10/15/2022 - 10:30
    Summary
    C-TRACT is a large, well-designed study of new treatments for vein damage caused by blood clots. The goal of the study is to understand whether new image-guided procedures (endovascular therapy or EVT) reduce the severity of Post-Thrombotic Syndrome (PTS) and improve quality of life. The long-term safety and costs of the EVT procedure(s) will also be considered. Volunteers will be randomly assigned (like the flip of a coin) to either high quality PTS care (lifestyle interventions, compression therapy, and medical therapy) or high quality PTS care AND endovascular therapy (stent placement to re-open blocked veins and, if needed, endovenous ablation to eliminate backflow in veins with leaky valves). After randomization, patients will be asked to return to their clinical research center for study visits at 2 Months, 4 Months, 6 Months, 12 Months, 18 Months, and 24 Months.

  8. Comparing Options for Management: Patient-Centered Results for Uterine Fibroids (COMPARE-UF)

    Submitted by centretek on Sat, 10/15/2022 - 10:30
    Summary
    Have you, a friend, or family member been diagnosed with uterine fibroids? If so, you or they may qualify to join over 10,000 women participating in the COMPARE-UF Registry to understand better treatment options for women diagnosed with uterine fibroids. Inova is seeking women to participate in a research study to better understand treatment options for uterine fibroids. The national study is called Comparing Options for Management: Patient Centered Results for Uterine Fibroids, or COMPARE-UF. Inova is one of only nine sites in the country participating. The study is led by Duke University.

  9. The Compassher2 Trials (Comprehensive Use Of Pathologic Response Assessment To Optimize Therapy In Her2-Positive Breast Cancer): Compassher2 Residual Disease (Rd), A Double-Blinded, Phase III Randomized Trial Of T-Dm1 And Placebo Compared With T-Dm1

    Submitted by centretek on Sat, 10/15/2022 - 10:30

  10. Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

    Submitted by centretek on Sat, 10/15/2022 - 10:30
    Summary
    This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Subscribe to